Semen News and Research

RSS

Semen is an organic fluid, also known as seminal fluid, that usually contains spermatozoa. It is secreted by the gonads (sexual glands) and other sexual organs of male or hermaphroditic animals and can fertilize female ova. The process of discharge is called ejaculation.

UB endocrinologist receives Junior Faculty Award to study effects of low testosterone in young men with type 2 diabetes

An endocrinologist in the University at Buffalo's School of Medicine and Biomedical Sciences has received a three-year $400,000 Junior Faculty Award from the American Diabetes Society to study the effects of low testosterone levels in young men with type 2 diabetes.

30 Oct 2010

Parasitic disease inflicts damage to women's reproductive organs: Research

Faculty of Life Sciences at the University of Copenhagen shows that the parasitic disease, commonly known as snail fever, or schistosomiasis, almost eats its way into women's reproductive organs. Today researchers from all over the world are gathering in Copenhagen to find out what can be done to halt the disease which is affecting millions of women in Africa.

29 Oct 2010

High urine BPA levels associated with decreased sperm quality

Increasing urine BPA (Bisphenol-A) level was significantly associated with decreased sperm concentration, decreased total sperm count, decreased sperm vitality and decreased sperm motility, according to a Kaiser Permanente study appearing in the journal of Fertility and Sterility.

28 Oct 2010

Scientists identify protein in urine can indicate prostate cancer risk

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

14 Oct 2010

Akonni receives NIJ grant to develop HCID system for SNP identification

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for diagnosing complex infectious and human diseases, today announced receipt of a nearly $500,000 Phase III Grant from the National Institutes of Justice (NIJ).

13 Oct 2010

FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal

Repros Therapeutics Inc. today announced that the Company has been granted a Type B meeting to be held on November 8, 2010 with the Division of Reproductive and Urologic Products to review the Company's Phase III pivotal efficacy protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

30 Sep 2010

New topical microbicide gel can prevent HIV transmission

Amyloid protein structures are best known for the troubles they pose in the brains of Alzheimer's patients. Now researchers are trying to exploit their presence in a very different place in semen to find a new way to stop HIV.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Study: Non-stick coating substance in semen reduces HIV transmission

A non-stick coating for a substance found in semen dramatically lowers the rate of infection of immune cells by HIV a new study has found.

24 Sep 2010

Celgene receives Paragraph IV Certification Letter on submission of ANDA for REVLIMID

Celgene Corporation today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration. The application requests authorization to manufacture and market generic versions of REVLIMID (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States.

3 Sep 2010

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene Corporation today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer.

25 Aug 2010

Brain can act as a hiding place for HIV virus: Study

Studies of the spinal fluid of patients given anti-HIV drugs have resulted in new findings suggesting that the brain can act as a hiding place for the HIV virus. Around 10% of patients showed traces of the virus in their spinal fluid but not in their blood.

23 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Research may puzzle out HIV transmission by sexual contact

The virus that causes AIDS may undergo changes in the genital tract that make HIV-1 in semen different than what it is in the blood, according to a study led by researchers from the University of North Carolina at Chapel Hill.

20 Aug 2010

Loyola University Medical Center to offer free prostate cancer screenings

More than 55 million American men are at risk for developing prostate cancer, according to the American Cancer Society. This year more than 27,000 men are expected to die of the disease, which is the second-leading cause of cancer death in men.

18 Aug 2010

Repros Therapeutics receives positive feedback from FDA for Androxal

Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.

9 Aug 2010

Bisphenol A may decrease sperm quality, concentration: Research

In one of the first human studies of its kind, researchers have found that urinary concentrations of the controversial chemical Bisphenol A, or BPA, may be related to decreased sperm quality and sperm concentration.However, the researchers are quick to point out that these results are preliminary and more study is needed. Several studies have documented adverse effects of BPA on semen in rodents, but none are known to have reported similar relationships in humans.

4 Aug 2010

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

A microbicide gel containing Gilead's HIV drug tenofovir used by women before and after sex has been shown to reduce their risk of HIV infection by nearly 40%, according to a study unveiled at the International AIDS Conference-AIDS 2010, Reuters reports

21 Jul 2010

IAS announces recipients of CNIHR grants

The International AIDS Society today announced the recipients of its first joint research grant programme, Creative and Novel Ideas in HIV Research. CNIHR grants, funded in partnership with the U.S. National Institutes of Health and the NIH-supported Centers for AIDS Research are designed to promote innovative research and new ideas from early stage investigators whose primary focus has previously been in fields of scientific inquiry other than HIV/ AIDS.

14 Jul 2010

Vitrified eggs as likely to produce on-going pregnancy as fresh eggs

Embryos derived from oocytes (eggs) cryopreserved by the vitrification method are just as likely to produce an on-going pregnancy as those involving fresh oocytes, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard today. Dr. Ana Cobo, Cryobiology Unit director at Institut Universitari - IVI Valencia, Valencia, Spain, told delegates that the results of her team's research would make egg donation both easier and safer in the future.

30 Jun 2010